Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Global Market Report 2024

The global exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market has grown strongly in recent years. It will grow from $5.24 billion in 2023 to $5.69 billion in 2024 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to increased prevalence of underlying conditions, advancements in diagnostic tools, pharmaceutical developments, rising global healthcare access.

The global exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market is expected to see strong growth in the next few years. It will grow to $7.67 billion in 2028 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to telemedicine and remote monitoring, data analytics and ai, patient education and support, regulatory changes and reimbursement policies. Major trends in the forecast period include personalized treatment approaches, development of novel therapies, minimally invasive diagnostics, collaborative care models.

The surge in diabetes cases is anticipated to fuel the expansion of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in the foreseeable future. Diabetes is a persistent metabolic ailment characterized by prolonged elevated blood sugar levels (hyperglycemia) resulting from either insufficient insulin production or the body's inefficiency in using the insulin it generates. EPI treatment, which encompasses pancreatic enzyme replacement therapy (PERT), proves beneficial in enhancing nutrient absorption for individuals with both diabetes and EPI. Moreover, it aids in bettering glycemic control for those with diabetes. For instance, as of November 2021, the International Diabetes Federation, a Belgium-based conglomerate of over 230 national diabetes associations, reported that an estimated 537 million adults (20-79 years old) were afflicted with diabetes in 2021. Furthermore, the total number of individuals grappling with diabetes is projected to escalate to 643 million by 2030 and 783 million by 2045. Consequently, the mounting prevalence of diabetes is a key driver for the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market's growth.

The surge in cases of gastrointestinal disorders is projected to drive the expansion of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in the foreseeable future. Gastrointestinal disorders encompass a range of medical conditions affecting the digestive tract, including the organs responsible for digestion. Managing gastrointestinal diseases relies significantly on exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics, which rectify enzyme deficiencies and promote effective nutrient digestion. For instance, as of June 2023, Crohn's and Colitis Canada, a non-profit organization based in Canada, estimated that over 322,600 Canadians were living with inflammatory bowel diseases (IBD) in 2023, constituting about 0.82% of the population. With the prevalence of IBD projected to persist, it is anticipated that approximately 470,000 Canadians will have IBD by 2035, roughly 1.1% of the population, or about 1 in every 91 individuals in the country. Consequently, the escalating incidence of gastrointestinal disorders is anticipated to be a driving force behind the growth of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market.

The exorbitant cost of treatment is anticipated to hinder the progress of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market throughout the forecast period. High treatment expenses in healthcare refer to the substantial financial outlays associated with medical care, often posing a considerable burden on individuals. The treatment modalities for exocrine pancreatic insufficiency (EPI) encompass nutritional management and pancreatic enzyme replacement therapy (PERT), which can be either generic or branded, leading to moderate to high costs incurred during the treatment process. As an illustration, in January 2021, as reported by the American Society of Clinical Oncology, a US-based professional organization representing physicians across all oncology sub-specialties, the out-of-pocket expenses for a 30-day supply of enzymes for Medicare beneficiaries could reach up to $1000. The lipase content per unit spanned from 3,000 to 40,000 USP units, with a per-unit list price ranging from $1.44 to $13.89. Consequently, the elevated treatment costs served as a significant constraint on the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market.

Prominent companies in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market are dedicated to pioneering innovative studies and solutions, like PACT-CP, to maintain their standing in the industry. For instance, in June 2021, Aimmune Therapeutics, a biopharmaceutical company based in the United States, introduced PACT-CP - a patient-centric chronic pancreatitis registry study. This initiative aims to gain deeper insights into the unmet needs and therapeutic challenges faced by patients dealing with EPI as a consequence of chronic pancreatitis (CP). Notably, it stands as the inaugural real-world registry study designed specifically for individuals with chronic pancreatitis. The study, which will track approximately 400 patients across 20 gastroenterology facilities in the United States, was developed in collaboration with patients and expert advisors. The PACT-CP Registry study constitutes a forward-looking, non-interventional research endeavor tailored for patients undergoing gastroenterology treatment and diagnosed with EPI stemming from chronic pancreatitis.

In September 2021, AzurRx BioPharma, a clinical-stage biopharmaceutical company headquartered in the United States, completed the acquisition of First Wave Bio Inc. for a total of $229 million. This pivotal acquisition has led AzurRx to rebrand as 'First Wave BioPharma Inc.' The strategic move signifies a significant expansion of the company's gastrointestinal (GI) development portfolio, propelling AzurRx into a prominent position in the realm of therapeutic interventions for inflammatory bowel diseases. First Wave Bio Inc., a US-based pharmaceutical entity, specializes in treating exocrine pancreatic insufficiency (EPI) in patients afflicted with cystic fibrosis and chronic pancreatitis.

Major players in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market are Pfizer Inc., Merck & Co. Inc., Janssen Pharmaceuticals Inc., AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca plc, Abott Laboratories, Medtronic plc, Solvay S.A., Laboratory Corporation of America Holdings (Labcorp), Organon group of companies Metagenics LLC, Allergan plc, Chiesi Farmaceutici S.p.A., Codexis Inc., Nordmark Arzneimittel GmbH & Co. KG, ChiRhoClin Inc., Digestive Care Inc., Alcresta Therapeutics Inc., Vivus Inc., Cilian AG, Bioserv Diagnostics Gmbh, Anthera Pharmaceuticals Inc., Aptalis Pharma Inc., First Wave BioPharma Inc., EagleBiosciences Inc., ScheBo Biotech AG.

North America was the largest region in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in 2023. The regions covered in exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary forms of treatments encompassed within exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics comprise nutritional management, pancreatic enzyme replacement therapy (PERT), and lifestyle adjustments. Nutritional management is a specialized healthcare approach utilizing nutrition and diet to address various medical and health conditions. Diverse diagnostic techniques are employed, including blood tests, magnetic resonance imaging (MRI), endoscopic ultrasonography (EUS), and computerized tomography (CT) scanning. Various types of medications, both generic and branded, are utilized, and these are distributed through a range of channels such as direct tender, retail pharmacy, third-party distributor, and others. These are availed by a diverse array of end users including hospitals, specialty clinics, homecare, diagnostic centers, research and academic institutes, among others.

This report provides exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market statistics, including exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics industry global market size, regional shares, competitors with a exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market share, detailed exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market segments, market trends and opportunities and any further data you may need to thrive in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics industry. This exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market consists of revenues earned by entities by providing dietary interventions and bile acid replacement therapy (BAR). The market value includes the value of related goods sold by the service provider or included within the service offering. The exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market also includes sales of Creon, Zenpep and Ultresa. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.